Table 2.

Reports of stereotactic body radiotherapy for adrenal oligometastases.

Authors	Study design	Number of patients	Primary organ	Dose/fractionation	Followup (months)	Outcomes	Toxicity
Nuyttens et al. [54]	Retrospective	30	Lung 20, others 10	16–50 Gy/4–10 fr (isocenter)	1–35	1-year LC: 44% 1-year OS: 55%	No grade > or =2
Tanvetyanon et al. [55]	Retrospective	48	Lung 24, Colorectal 12, others 12	36 Gy/3 fr (covering PTV)	3–63 (median, 17)	2-year LC: 90%	Adrenal deficiency: 1
Chawla et al. [56]	Retrospective	7	Lung 19	30–60 Gy/1–27 fr	NA	2-year OS: 33%	NA
Casamassima et al. [57]	Retrospective	19	Lung 4, others 3	16–27 Gy/1–3 fr (covering PTV)	1–60 (median, 38)	1-year LC: 63% MS: 8 months	NA

Abbreviations: LC: local control rate; OS: overall survival rate; NA: not available; MS: median survival time.